Pancreatic Cancer
Conditions
Keywords
Pancreatic cancer, Rexin-G, Treatment
Brief summary
The goal of the adaptive trial design is to determine the over-all safety of escalating doses of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to support a Phase II registration protocol.
Detailed description
The clinical trial is a safety and efficacy study using escalating doses of Rexin-G that incorporates a Phase II component that will evaluate the efficacy of Rexin-G using an adaptive trial design. Each treatment cycle will be six weeks: four weeks of treatment and two weeks of rest. Unlike a standard Phase I protocol, eligible patients may have repeat cycles after the safety data and objective tumor response/s are recorded. Continued Rexin-G treatment will enable the targeted genetic medicine to catch up with tumor growth, halt disease progression, and reduce tumor burden. The treatment strategy is to achieve tumor control as quickly as safely possible. The goal of the adaptive trial design is to confirm the over-all safety of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to support a Phase II/III pivotal trial.
Interventions
GENETICRexin-G
Dosing Schedule: 1 x 10e11 cfu 2 times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
Sponsors
Epeius Biotechnologies
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically or cytologically confirmed recurrent or metastatic pancreatic cancer that has failed gemcitabine and that is measurable. 2. Adequate hepatic function: Total bilirubin \< 2.0 mg/dL (upper limit included); AST/ALT \< 2x institutional norm; alkaline phosphatase \< 2.5x upper limit of institutional norm unless the patient has extensive bone metastases. Patients with elevated alkaline phosphatase due to extensive liver disease will be excluded from study; albumin \> 3.0 mg/dL. There must be no substantial ascites. PT and PTT must be within normal limits. 3. Performance status must be \< 1 (ECOG 0-1) with a life expectancy of at least 3 months. 4. Hemoglobin \> 9 gms% 5. Absolute granulocyte count \> 1000/uL, and platelet count \> 100,000/uL. 6. Serum creatinine of less than 1.5 mg%. 7. There must be no plans for the patient to receive further cancer therapy from the date of enrollment until the completion of the 6-week follow-up visit. 8. Accessibility of peripheral or central IV line 9. Age \> 10 years 10. Patients will be off chemotherapy for a minimum of 4 weeks prior to initiation of therapy and should have recovered to Grade 1 or less toxicity. 11. The ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
1. Prior malignancy, except for non-melanoma skin cancer, stage 1 breast cancer, CIS of cervix from which the patient has been disease-free for 5 years. 2. Woman who are pregnant or nursing 3. Fertile patients unless they agree to use barrier contraception (condoms and spermicide jelly) during the vector infusion period and for six weeks after infusion. Male patients must agree to use barrier contraception. 4. Patients who are transfusion dependent (more than one transfusion per month) 5. Patients with medical, psychiatric, or social conditions that would compromise successful adherence to this protocol. 6. Patient who do not meet the inclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical toxicity (DLT and MTD) as defined by patient performance status, toxicity assessment score, hematologic, and metabolic profiles. | 24 |
Secondary
| Measure | Time frame |
|---|---|
| To identify an objective tumor response to Rexin-G | 24 months |
Countries
United States
Outcome results
None listed